

## AUSTRALIAN DELEGATION

---

### **Bioanalytical Lab** 生物分析實驗室

360biolabs	1
Agilex Biolabs	2
Crux Biolabs	3
Resolian Bioanalytics	4

### **Clinical Trial Logistics Services** 臨床試驗藥品物流管理

Cryosite	6
Taikun Pharma	7


### **Clinical Trial Site** 臨床試驗中心

CMAX Clinical Research	9
Linear Clinical Research	10
Monash Health	11
Nucleus Network	12
Scientia Clinical Research	13
Veritus Research	14

### **CRO** 臨床試驗受託機構

Alithia Life Services	16
Avance Clinical	17
CMIC Asia-Pacific (Australia)	18





## AUSTRALIAN DELEGATION

---

Emerald Clinical	19
Greenlight Clinical	20
HiRO	21
ICON Clinical Research	22
Mobius Medical	23
Momentum Clinical Research	24
Novotech	25
Precision for Medicine	26
PrecisionMed Research	27
Southern Star Research	28

### Cancer Patient Trials Matching 癌症患者臨床試驗配對


Omico	30
-------	----

### R&D Tax Incentive 研發稅務獎勵

Global R&D	32
------------	----

### Innovative Biotech 創新生技

Audeara Limited (聽力創新技術)	34
Invion Limited (新型光動力癌症療法)	35
TrialScreen (受試者 AI 招募平台)	36



# Bioanalytical Lab

## 生物分析實驗室

# 360biolabs



👤 Debbie Lee, Business Development Manager

☎ +61 422 817 792

✉ Debbie.Lee@360biolabs.com

🌐 [www.360biolabs.com](http://www.360biolabs.com)

## Company Introduction

---

360biolabs is Australia's most comprehensive bioanalytical laboratory, providing a diverse range of assay services to support clinical trial programs for new therapeutics, vaccines and diagnostics in a quality-assured environment.

We offer a full suite of pharmacokinetic (PK) and pharmacodynamic (PD) endpoints, including small and large molecule PK, ADA, nAb, biomarkers (MSD, ELISA, SIMOA, Luminex, ELISpot), flow cytometry, immunology, molecular and virology assays, supported by globally recognised quality systems under GLP, GCP and ISO/IEC 17025. 360biolabs upholds rigorous quality standards and requirements set by global regulatory bodies such as the

FDA, EMA, and others.

Across the Eastern coast of Australia we have purpose-built laboratories (BSL2 and BSL3) in Melbourne and Brisbane, with continued expansion into Sydney coming soon. With our BioAgilytix global network, we also have laboratories across the United States and Europe, available for seamless assay transfer for Phase 2+ studies. Each of our laboratories reflects our unwavering commitment to scientific excellence, innovation, and uncompromising quality.

With a decade of Enabling Future Medicines, 360biolabs has built world-class bioanalytical excellence advancing global clinical research.

## Areas of Interest in Taiwan

---


Biotech, Pharma Companies for clinical trials.


Delivering bioanalytical expertise for a wide-range of assays and therapeutic areas.




# Agilex Biolabs



 Xhin Yin Ngo, Business Development Manager

 +61 449 201 389

 [Xhin.Yin.Ngo@agilexbiolabs.com](mailto:Xhin.Yin.Ngo@agilexbiolabs.com)

 [www.agilexbiolabs.com](http://www.agilexbiolabs.com)

## Company Introduction

---

Established in 1996, Agilex Biolabs is Australia's first and largest dedicated bioanalytical laboratory, with 30 years of experience supporting global clinical development programs. Backed by industry-leading platforms including Sciex Triple Quad 7500+ LC-MS/MS, MSD QuickPlex SQ 120 and Cytex Aurora, Agilex delivers PK, ADA, biomarker, and flow cytometry solutions across a broad range of therapeutic areas.


FDA-inspected, ISO/IEC 17025 accredited, OECD GLP recognised, and BSI ISO 27001:2022 certified, Agilex is a trusted partner for sponsors conducting clinical trials in Australia.

Running a clinical trial in Australia? Reach out to Agilex Biolabs and discover why sponsors have trusted us for nearly 3 decades.

## Areas of Interest in Taiwan

---

Australian clinical development, First-in-Human (FIH), Phase I-III studies, Taiwanese and Asian biotechs, Australia trial placement, PK, ADA, biomarkers, immunology, flow cytometry, small molecules, biologics, radiopharmaceuticals, cell & gene therapies, vaccines



## Company Introduction

---

Crux Biolabs is a specialist Australian bioanalytical laboratory supporting clinical development through expert PBMC processing, pharmacodynamics, and pharmacokinetics - across both large and small molecules.

From complex biomarker, flow cytometry, and ADA assays to end to end PK analysis, our scientists design, customise, and validate fit for purpose methods in our ISO/IEC 17025 accredited Melbourne laboratory.

To accelerate study timelines, we offer pre

validated platforms across key technologies including flow cytometry and Meso Scale Discovery (MSD), enabling faster method deployment without compromising scientific rigor.


No two studies are the same. That's why Crux operates as an extension of your internal team, combining deep technical expertise with practical, study focused execution to deliver data you can trust.

Crux Biolabs — where science leads.

## Areas of Interest in Taiwan

---

clinical trials, clinical research, bioanalytical services, biotechnology, pharmaceuticals, immunology, biomarkers



# Resolian Bioanalytics



👤 Jason Wang, Site President

☎ +61 404 790 582

✉ [jwang@resolian.com](mailto:jwang@resolian.com)

🌐 [www.resolian.com](http://www.resolian.com)

## Company Introduction

---


Resolian is a leading global Contract Research Organization (CRO) providing specialized services in GxP and non-regulated bioanalysis, drug metabolism/pharmacokinetic (DMPK), and GMP CMC analytical and materials science. Its

team of more than 500 experts across the US, UK, and Australia, Resolian supports pharma and biotech companies' programs throughout the entire drug development continuum

## Areas of Interest in Taiwan

---

Biotech or pharma who has the need for global clinical trials, especially in Australia, China, US and UK



Clinical  
Trial Logistics  
Services

臨床試驗藥品物流管理

Cyosite



👤 Jon Fairweather, Business Development Manager

☎ +61 406 646 796

✉ [jon.fairweather@cryosite.com](mailto:jon.fairweather@cryosite.com)

🌐 [www.cryosite.com](http://www.cryosite.com)

## Company Introduction


---

Cryosite is the trusted partner for companies requiring specialist clinical trial and commercial storage and logistics solutions across the ANZ region.

We provide critical supply chain support for advanced medicinal therapies, human therapeutics and medical device products,


and offer secure, compliant, and temperature-controlled storage and validated freight solutions.


Our streamlined, GMP-aligned processes enable rapid deployment to clinical sites or downstream distribution networks, whilst ensuring full product integrity.




# Taikun Pharmaceutical Technology Pty Ltd



 Jimmy Huang, Director, Business Development

 +886 921513106

 jimmy.huang@taikunpharma.global

 [www.taikunpharma.com/home](http://www.taikunpharma.com/home)

## Company Introduction

---


Taikun Pharma is an Australia-founded company dedicated to supporting clinical-stage Investigational Medicinal Product (IMP) management, helping biotech and pharmaceutical partners navigate the complexities of global clinical trials. Founded in 2019, Taikun has delivered over 800 projects, with nearly 200 global clinical trials conducted across multiple regions, reflecting strong execution capabilities and hands-on experience in international clinical supply operations.

Taikun Pharma delivers one-stop, end-to-end Clinical Supply Management (CSM) across the US, China, Australia, and the EU. We integrate global depots with our proprietary Ozone ONE IRT/RTSM system to streamline comparator sourcing, specialized packaging, and temperature-controlled distribution. By harmonizing digital tracking with EU QP services, Taikun ensures GXP-compliant, highly flexible, and cost-effective CSM solutions tailored to your study's global scale, complex timelines, and budgetary requirements.

## Areas of Interest in Taiwan

---

Biotech companies, Biopharma companies, Clinical stage and Phase I-III, Randomization, Blinding study, MRCT, QP in EU



# Clinical Trial Site

## 臨床試驗中心

# CMAX Clinical Research



👤 Harry Li, Senior Business Development Manager

☎ +61 444 561 814

✉ [harry.li@cmx.com.au](mailto:harry.li@cmx.com.au)

🌐 [www.cmx.com.au](http://www.cmx.com.au)

## Company Introduction

---


CMAX is one of Australia's largest and most experienced early phase clinical trial units. Centrally positioned in Adelaide, South Australia, CMAX is located opposite the Royal Adelaide Hospital and adjacent to the innovative Adelaide BioMed City precinct.

As Australia's longest-operating early phase unit, CMAX conducts successful world-leading research for local and international clients, specialising in a range of early-phase trials and first-time-in-human studies (FTIH).

## Areas of Interest in Taiwan

---


FIH studies (Healthy volunteers and patients), early phase biotechs, CROs




# Linear Clinical Research

# linear

Human Breakthroughs

 Ryan Kafoure, Chief Business Development Officer

 +61 418 765 065

 [rkafore@linear.org.au](mailto:rkafore@linear.org.au)

 [www.linear.org.au](http://www.linear.org.au)

## Company Introduction

---

Linear Clinical Research provides the most comprehensive clinical trial site capability in Australia, delivered across three specialist facilities, including the purpose-built Joondalup Early Phase Centre and Australia's first private hospital dedicated to cancer and other therapeutic trials, the Advanced Clinical Trial Centre.

Leveraging Australia's rapid trial start-up environment and eSource technology, Linear can deliver rapid trials across all phases in healthy volunteers and patient groups, including next generation molecules such as RNA, bi/trispecifics and cell therapy.

As a profit-for-purpose company and subsidiary of the Harry Perkins Institute of Medical Research, Linear holds dedicated Medical Directors across our core portfolios of Phase I healthy volunteer, oncology, haematology, immunology and cardiometabolic, with capability extending across a broad range of therapeutic areas to meet your programme needs.


Australia offers a fast regulatory framework without requiring an IND application, and eligible pre-revenue biotechs benefit from a 43.5% R&D cashback incentive.


## Areas of Interest in Taiwan


---

Early Phase, Clinical Trials, Phase I, Phase 2a, Phase 1b, Phase 1, FIH, oncology, haematology, immunology, cardiometabolic, research, clinical



 Tam Nguyen, Director Research & Innovation

 +61 422 596 302

 Tam.Nguyen@monashhealth.org

 [monashhealth.org/about/research/](https://monashhealth.org/about/research/)

## Company Introduction

---

Monash Health exists to reimagine care, so that people can live their best lives.

We deliver world-leading care for the community we serve, with over 175 years of experience. We do this in a way that is safe and equitable, ensuring our consumers and those who care for them are at the centre of everything we do.

As a leading academic health service, our curiosity pushes us to innovate and improve

lives locally, nationally and globally. We're committed to providing tomorrow's care today by integrating research, teaching and training into everyday practice.

Our team of 24,000 people are full-hearted, open minded and all in. Together, we provide more than 250 integrated services for every stage of life at over 50 locations and in the community across south-east Melbourne, Victoria.

## Areas of Interest in Taiwan

---

Digital Health

Medical Devices

Clinical Trials

Precision Medicine

Translational Research

Biotechnology

AI in Healthcare

Hospital Partnerships

Regenerative Medicine

Diagnostics


Health Innovation

Research Collaboration

Pharmaceutical Partnerships


Cancer Research


Healthcare Technology





# Nucleus Network



 Chris Hickey, Chief Business Development Officer

 +1 (443) 685-5800

 [c.hickey@nucleusnetwork.com](mailto:c.hickey@nucleusnetwork.com)

 [www.nucleusnetwork.com](http://www.nucleusnetwork.com)

## Company Introduction

---

Nucleus Network is the only global provider dedicated to early phase clinical trials, with units in Australia, the USA and the UK. Our unified network provides sponsors access to all three major regulatory markets through one trusted partner.


With more than 2,500 early phase studies and 1,500 First in Human trials over 30 years, we are the most experienced early phase team worldwide. We are recognised for managing

complex and adaptive designs with confidence, supported by proven scientific leadership and operational delivery. Alongside First in Human expertise, we conduct the full spectrum of clinical pharmacology studies, giving sponsors the depth, consistency and participant access to accelerate new medicines. One Network. Multiple Pathways. The Power of a Unified Global Network.

## Areas of Interest in Taiwan

---

Phase I Clinical Trials



# Scientia Clinical Research Limited



👤 Chris Stellatos, Director, Corporate Development

☎ +61 404 185 522

✉ [chris.stellatos@scientiaclinicalresearch.com.au](mailto:chris.stellatos@scientiaclinicalresearch.com.au)

🌐 [www.scientiaclinicalresearch.com.au](http://www.scientiaclinicalresearch.com.au)

## Company Introduction

---

Scientia Clinical Research is one of Australia's leading Phase 1 clinical trial units and is the only Phase 1 site based in Sydney that operates as a not for profit. Co-located at the Prince of Wales Hospital, with whom we have a service agreement (including emergency service), Scientia has extensive experience, delivering over 275 clinical trials with a team experienced Principal Investigators and senior management team, with over a century of combined clinical trials experience.

Scientia has the ability to support highly complex First-in-Human trials, in both healthy volunteer and patient trials (including FIH Oncology) as well as a range of BE/BA, ethno


bridging, and other traditional PK/PD trials. We collaborate with clinical CROs to deliver a full-service offering and frequently work with sponsors based in East Asia.

We have streamlined processes for contracting and Study Start-up, to support sponsors with rapid timelines. Our team connects with leading Key Opinion Leaders across the state of NSW allowing access to participants from a range of different therapeutic indications. As a fully Australian own and operated service provider, Scientia offers high quality data recognised by global regulators such as the FDA and EMA, and a track record of recruitment success across our projects.

## Areas of Interest in Taiwan

---


Biotech, pharma, sponsors, Clinical CROs, Phase 1 trials in Australia




# Veritus Research




VERITUS  
RESEARCH

 Marco Rauseo, Business Development Manager

 +61 493 448 054

 [Marcorauseo@veritusresearch.com](mailto:Marcorauseo@veritusresearch.com)

 [www.veritusresearch.com](http://www.veritusresearch.com)

## Company Introduction

---

Veritus Research is a groundbreaking clinical research organisation that is revolutionising the field of Clinical Research within the Australian biomedical community. Our mission is to challenge the traditional norms by decentralising the conduction of studies that were previously limited to tertiary centres.


At Veritus, we defy conventional thinking, pioneering a new way forward with our standalone custom-built, state-of-the-art

Clinical Research facility. This cutting-edge facility specialises in conducting Early Phase and First In Human (FIH) studies, providing a clinically safe environment for participants. Our commitment to excellence drives us to deliver the highest quality data to our Sponsors and stakeholders, leverage the latest advancements in technology within our modern and luxurious facility.

## Areas of Interest in Taiwan

---

Clinical Trials, First in human studies, Phase I, CRO





# CRO

## 臨床試驗受託機構


# Alithia Life Sciences Pty Ltd



 Jovana Milosevic, Chief Commercial Officer

 +61 449 035 229

 [jovana.milosevic@alithialifesciences.com](mailto:jovana.milosevic@alithialifesciences.com)

 [www.alithialifesciences.com](http://www.alithialifesciences.com)

## Company Introduction

---

Alithia Life Sciences is proudly Australian-owned, full-service CRO partnering with pharmaceutical, biotechnology, medical device companies, and institutional research groups, offering flexible, personalised solutions to deliver high-quality clinical development programs across Australia and globally.

Our team members have on average 15-20+ years of combined industry and operational experience, across a broad range of trials and therapeutic areas including:

- FIH studies
- Neurology
- Devices
- Endocrinology
- Oncology

- Women's health
- Ophthalmology
- Gastroenterology
- Cardiovascular
- Rare and Paediatric diseases
- Vaccines and more.

Alithia supports FIH and Phase I–III clinical trials, with expertise in managing investigational products across drugs, devices, Cell and Gene therapies, and combination therapies.

From early-stage concept through FDA approval, partners rely on us to guide every step of the clinical development journey with scientific rigor, operational excellence, and a strong commitment to advancing human health.

## Areas of Interest in Taiwan

---

Biotech, Medtech, Pharma, FIH, Phase I- Phase III, Oncology, Neurology, Dermatology, Cardiology, Gastroenterology, Vaccines, Ophthalmology, Endocrinology, Women's Health, Device, C&GT, Paediatric & Rare diseases.

# Avance Clinical



AVANCE CLINICAL

👤 Kelly Yang, Associate Director  
Operations Taiwan

☎️ +886 978 965 628

✉️ Kelly.Yang@avancecro.com

🌐 www.avancecro.com

## Company Introduction

---

Avance Clinical is a full-service global Contract Research Organization (CRO) with more than 30 years of experience accelerating drug development for biotech innovators worldwide. Headquartered in Australia, with operations across Australia, Europe, the United States, and Asia, we specialise in early-phase to proof-of-concept clinical trials across oncology, CNS, rare diseases, renal and cardiometabolic disorders, and advanced therapies including cell and gene treatments.


Our Global model enables biotechs to leverage Australia's streamlined regulatory environment

- no IND requirement, ethics approval within 5–6 weeks, and up to 43.5% R&D tax rebate - to generate high-quality, cost-efficient early data accepted by the EMA, FDA, and other major regulators. Through our GlobalReady™ framework, we ensure seamless scientific and operational continuity from first-in-human studies through multi-regional Phase II/III programs with access to Asia Pacific and North America, reducing development risk, accelerating timelines, and preserving capital for biotech innovators pursuing global market success.


## Areas of Interest in Taiwan


---


Taiwanese biotechs, Asian biotechs, Phase I and Phase II, US and European CROs interested in Taiwan market.






 Lingo Chiang, Business Development Manager

 +886 956 633 163

 [lingo-chiang.gh@cmicgroup.com](mailto:lingo-chiang.gh@cmicgroup.com)

 [en.cmicgroup.com](http://en.cmicgroup.com)

## Company Introduction

---

CMIC supports active clinical trials across more than 12 countries in the APAC region. We have supported clinical trials over a range of therapeutic areas, with specialization in oncology, cardiovascular diseases, ophthalmology, endocrinology and metabolic diseases, and dermatology. We can help you navigate the regulatory landscape, identify clinical trial sites, and recruit patients. We also offer a variety of cost-saving solutions to help you get your product to market faster, as the APAC market offers numerous benefits, including faster approvals.

CMIC's Australia office was established in


2019 in Brisbane, Australia to provide full operational services in the execution of clinical trials under the Pharmaceutical Value Creator (PVC) model. With experienced team members with experience with projects of global and local scales, we understand the country's biopharmaceutical and healthcare markets.

Our combination of industry experience and expertise across a broad spectrum of therapeutic areas and phases can help you accelerate clinical and commercial success to deliver better medicines, sooner.

## Areas of Interest in Taiwan

---

clinical trials services in APAC region



# Emerald Clinical



**EMERALD**  
CLINICAL TRIALS

👤 Clara Yang, Inside Sales

☎ +886 938 102 571

✉ Cyang1@emeraldclinical.com

🌐 emeraldclinical.com

## Company Introduction

---

Since its inception, Emerald Clinical — a global, full-service CRO with 25+ years of experience has been known as one of the key leaders especially in renal and cardiometabolic studies, providing scientific leadership in these therapeutic areas. Headquartered in Singapore, we support Phase I–IV and real-world studies across all therapy areas through a team of 1000+ professionals working in 40+ countries, backed by a collaborative network spanning 70+

locations worldwide.

We partner with more than 160 biotech companies and 15 of the world's top 20 pharmaceutical firms, providing scientific excellence and operational expertise to advance innovative therapies.

Our core specialties include Renal, Oncology, Autoimmune, Ophthalmology, Cardiometabolic, and Early Phase development.

## Areas of Interest in Taiwan

---

### Companies interested in:

- Clinical CRO Services (Phases I - IV)
- Patient Recruitment & Site Engagement
- Data Management & Biostatistics
- Clinical Trial Monitoring & Site Management
- Safety & Pharmacovigilance
- Study Design & Start-Up


- Medical Affairs & Scientific Leadership
- Renal / Kidney
- Cardiometabolic
- Oncology
- Autoimmune
- Ophthalmology
- Specialized Early Phase (P1-2) Support


# Greenlight Clinical




Innovative clinical research solutions

 Robert Lin, Chief Executive Officer

 +61 2 9191 0640

 robert.lin@greenlightclinical.com

 www.greenlightclinical.com

## Company Introduction

---

Greenlight Clinical (GLC) is a physician-led full-service specialist CRO established in 2016 in Sydney, Australia specializing in early phase clinical trials. Combining medical expertise, deep industry knowledge, and a close relationship with clinical research sites, we specialize in:


- First-in-Human,
- Phase I / Phase Ib-IIa /Phase III,
- Translation from healthy volunteers to in-patient populations,
- Cross regulatory harmonization of trials and design,
- Strong expertise and experiences in medical devices registration.

GLC provides customized clinical research solutions to expedite pharmaceutical and biotech product development at high standards of quality and ethics in clinical research. We offer customized solutions to fit the specific needs of our clients, particularly small and mid-sized biotech companies. Our agile and flexible approach allows us to adapt to different study requirements and timelines, ensuring a smooth and successful trial process.

## Areas of Interest in Taiwan

---

Ophthalmology, Oncology, Gene and cell therapies including stem cell, Medical Devices



# Harvest Integrated Research Organization (HiRO)



👤 Sam Adamson, Director

☎ +61 409 014 923

✉ sam.adamson@harvestiro.com

🌐 harvestiro.com

## Company Introduction

---

Harvest Integrated Research Organization (HiRO) is a globally oriented, innovative clinical research organization (CRO). With global operations and integration capabilities, HiRO provides a full range of cross-border solutions and services to its clients, including early pre-clinical strategic planning, clinical trial design, regulatory, pharmacovigilance, statistics, data management, end-to-end


project management, and clinical and medical monitoring services.

As an emerging global CRO, HiRO strives to become a market-leading, integrated global clinical research organization that works collaboratively with biotech and pharmaceutical companies to bring new products from the laboratory to the market, providing more effective solutions for patients worldwide.

## Areas of Interest in Taiwan


---


Biotech, Pharma, Full Service Study




# ICON Clinical Research



 Liza Yeo, Senior Director Business Development

 +61 427 803 162

 [Liza.Yeo@iconplc.com](mailto:Liza.Yeo@iconplc.com)

 [www.iconplc.com/contact/global-office-locator](http://www.iconplc.com/contact/global-office-locator)

## Company Introduction

---


ICON is the world's largest pure-play clinical research organisation. From molecule to medicine, we advance clinical research by providing outsourced development and commercialisation services to pharmaceutical, biotechnology, medical device and government, and public health organisations. We develop new innovations, drive emerging therapies

forward and improve patient lives. ICON offers the most comprehensive suite of integrated clinical development services in the industry. We've designed fully customisable solutions to help our customers achieve their goals across a seamless delivery model, spanning their product's entire lifecycle.

## Areas of Interest in Taiwan

---

Biotech, Pharma and Medtech customers



# Mobius Medical



**mobius**<sup>TM</sup>  
MEDICAL

👤 Stefan Czyniecki, Co-Founder and Principal

☎ +61 414 669 565

✉ stefan@mobius-cro.com

🌐 www.mobius-cro.com

## Company Introduction

---

Mobius Medical is a specialized CRO focusing on medical device, pharmaceutical, and diagnostics clinical trials. With offices in Australia and the United States, we combine global expertise with regional insight to help sponsors accelerate development, reduce risk, and navigate regulatory pathways efficiently.

We provide full-service clinical trial support from early feasibility through pivotal studies (medical device), Phase I through to Phase IV (pharmaceutical), regulatory strategy support, clinical operations, project management, site monitoring, biostatistics, data management,

safety oversight, and medical writing.

Leveraging Australia's fast start-up timelines, high-quality data standards, and R&D Tax Incentive, Mobius enables rapid and cost-effective early-phase studies. We also support U.S. Early Feasibility Studies (EFS) and IDE-approved trials, creating seamless development pathways between Australia and the U.S.

Known for responsive communication, operational excellence, and scientific integrity, Mobius partners with innovators worldwide to bring safe and transformative medical technologies to market.

## Areas of Interest in Taiwan

---

Clinical Trial Management

Medical Device Clinical Trials

Early Feasibility Studies (EFS)

Regulatory Strategy & Submissions

IDE, IND studies

Cell & Gene Therapy Clinical Development

Biotech & MedTech; Commercialisation Support

Australia/New Zealand Clinical Trial Execution

FDA, EMA & TGA Regulatory Pathways

Data Management, Biostatistics & GCP

Compliance

# Momentum Clinical Research



**Momentum**  
Clinical Research

- 👤 Kacey Murphy, Chief Commercial Officer
- ☎ +64 221 368 563
- ✉ kacey.murphy@momcr.co.nz
- 🌐 [www.momentumclinicalresearch.com.au](http://www.momentumclinicalresearch.com.au)

## Company Introduction

---


Momentum Clinical Research is Australasia's largest full phase Clinical Trials Site Network with 19 sites across Australia and New Zealand. We deliver end-to-end trials from First-in-human to Phase IV across a broad range of Therapeutic Area's, taking Healthy Volunteer studies into patient cohorts seamlessly.

By combining centralised efficiencies across feasibility, start-up and recruitment with strong site leadership we provide sponsors with a faster and seamless experience across all of our sites.

## Areas of Interest in Taiwan

---

Biotech's, Pharmaceutical, Clinical Research, CRO's



# Novotech



## NOVOTECH™

Biotech's Partner at Every Phase

- 👤 Calvin Tzeng, BD Director
- ☎ +886 2 8979 3442
- ✉ Calvin.Tzeng@novotech-cro.com
- 🌐 [novotech-cro.com/ct](http://novotech-cro.com/ct)

## Company Introduction

---


Novotech is a globally recognized full-service clinical research organization (CRO) and scientific advisory partner for biotech and small- to mid-sized pharmaceutical companies seeking to advance drug development. With

deep therapeutic and regulatory expertise and an expansive global footprint across the Asia-Pacific region, North America, and Europe, Novotech offers clients an accelerated path to bring life-changing therapies to market.

## Areas of Interest in Taiwan

---

- Clinical CRO from Phase I to Phase IV (APAC/US/EU)
- Medical and Regulatory consulting
- Early Phase Trial in Australia
- Biometrics and Data Management
- Virtual Trial/DCT/Real World Data
- Central Lab and Bioanalytical Lab



# Precision for Medicine



-  James Cheong, SVP Asia Pacific, Clinical Solutions
-  +65 9786 6426
-  James.Cheong@precisionformedicine.com
-  precisionformedicine.com

## Company Introduction

---

Precision for Medicine is a global clinical CRO headquartered in the United States with more than 20 years of experience and over 3,500 employees worldwide. We specialize in oncology, rare disease, and autoimmune research, providing end to end support for Phase I–III clinical trials across North America, South America, Europe, and the Asia Pacific region. Our integrated services include regulatory strategy and consulting, clinical operations, biostatistics, medical affairs, safety and pharmacovigilance, and advanced translational and bioanalytical laboratory capabilities.

Our presence in Asia Pacific was established with the opening of an Australian office almost

10 years ago. Since then, we have successfully delivered more than 100 Ph I–III trials for our sponsors who are aware of the advantage of conducting clinical trials in Australia.

Precision for Medicine is part of Precision Medicine Group (PMG), which was founded to address the challenges of advancing new therapies from clinical development through commercialization—ensuring innovative treatments reach the patients who need them. PMG's subsidiary, Precision AQ, focuses on global market access, investor relations, and commercialization readiness, offering evidence generation, value strategy, and deep scientific insight to accelerate decision making and support successful product launches.

## Areas of Interest in Taiwan

---

Biotech/Pharma focused on Oncology, Autoimmune and Rare Disease, Phase I trials in Australia, MRCT trials in US/EU/APAC, Regulatory Strategy by ex-US FDA Leaders, Biomarker Strategy and Assay Development, Specialty Lab Service

# PrecisionMed Research Pty Ltd



👤 Jane Chiu, Executive Director

☎ +61 467 745 906

✉ [janechiu@precision-med.com.au](mailto:janechiu@precision-med.com.au)

🌐 [www.bestat.com.tw](http://www.bestat.com.tw)

## Company Introduction

---

PrecisionMed Research is a newly established Australian Contract Research Organisation (CRO) providing comprehensive clinical operational services, with a particular focus on early-phase studies. Our CEO, Jane Chiu, brings over 30 years of intensive experience across healthcare, pharmaceutical sectors, and the global CRO industry within both Taiwan and Australia.

Our Australian team possesses deep industry expertise across a broad spectrum of therapeutic areas. By leveraging our dual-


market presence, we assist Taiwanese clients in accelerating their clinical trial success and efficiently delivering projects to the next phase of development.

To offer a truly end-to-end service, PrecisionMed collaborates with Bestat Pharmaservices—one of Taiwan's largest CROs—for advanced data analysis solutions. Furthermore, we partner with local Australian specialists to support IP and blood sample logistics, biological and PK testing, and the navigation of the Australian R&D tax incentive.

## Areas of Interest in Taiwan


---

Our focus is on providing full Phase 1 clinical trials to clients in Taiwan. We are looking forward to connecting with clients who are currently in this trial phase.





# Southern Star Research Pty Ltd



 Amanda Jubb, Head Of Asia

 +61 2 9011 6266

 [ajubb@southernstarresearch.com](mailto:ajubb@southernstarresearch.com)

 [www.southernstarresearch.com](http://www.southernstarresearch.com)

## Company Introduction

---

Southern Star Research is a full-service contract research organisation (CRO) supporting biotech, pharmaceutical, and medical device companies. It simplifies and accelerates the clinical trial process, helping sponsors bring treatments to market faster.

With a global network of experts, Southern Star Research delivers high-quality medical writing, clinical monitoring, project management, biostatistics, data management

and quality assurance services to meet the unique needs of each study.

Southern Star's global reach allows it to support multi-regional trials with local expertise and in compliance with international standards.

The company stands as trusted advisors, sharing knowledge, offering guidance, and engaging in collaborative decision-making to accelerate clinical trial outcomes.

## Areas of Interest in Taiwan

---

Early Phase Clinical Development, Vaccine Development, Biotech, New Drug Development, Pharmaceutical Company




# Cancer Patient Trials Matching

## 癌症患者臨床試驗配對

**Omico**



 Dr Eve Chao Wang, Senior Business Development Manager

 +61452318273

 e.wang@omico.org.au

 omico.org.au

## Company Introduction

---

Omico is a national, independent, not-for-profit precision oncology organisation accelerating access to precision cancer medicine and biomarker-led clinical trials across Australia.

By leveraging a nationwide network of expertise and resources, we aim to improve outcomes for all Australian cancer patients through science-led advances in prevention and treatment of cancer.

Through our Cancer Screening Program (CaSP), Omico enables comprehensive genomic profiling for eligible cancer patients and uses molecular and clinical insights to match patients to targeted treatments and clinical trials.

This globally unique model positions Australia

as an international hub for cancer research and supports a rich, integrated real-world data resource.

Omico's real-world data is prospectively consented and purpose-built, bringing together genomic data with detailed clinical, treatment and outcomes information to create a connected view of the patient journey in a single dataset.

This depth and connectivity, combined with Omico's clinical, genomic and translational expertise, enables Pharma, Biotech, CRO partners, Research partners and Government agencies to generate clearer evidence and make more confident decisions, earlier, and with greater efficiency.

## Areas of Interest in Taiwan

---

biomarker-led clinical trials; biotech; pharma; targeted therapies; real-world evidence

# R&D Tax Incentive

## 研發稅務獎勵

# Global R&D Pty Ltd



👤 Pavel Reddy, Director

☎ +61 415 557 542

✉ pavel@globalrnd.com.au

🌐 globalrnd.com.au

## Company Introduction

---

Global R&D is a dedicated R&D Tax Incentive consultancy with a truly global reach. We provide valuable, expert guidance on all aspects of R&D Tax matters to companies across Australia, China, EU, Singapore, South Korea, Taiwan, UK, and the USA.

Working actively across the start-up and SME community, Global R&D provides R&D Tax Advisory services across the various Tech sectors, including but not limited to AgriTech, BioTech, FinTech, Life Sciences, MedTech, Manufacturing, Mining and Pharma.

In addition to providing insightful and expert advice, trusted guidance, and focused resources to ensure compliant R&D Tax Incentive claims, Global R&D has already enabled clients to receive cash refunds that exceed client expectations.

We pride ourselves in providing significant pro bono time and effort to various incubators, accelerators and their founder/techpreneur

communities.

Founder and Director, Dr Pavel Reddy comes with 18+ years of R&D Tax expertise, having worked for a Big Four firm, as well as another local respected R&D Tax advisory firm. With a Doctorate in Biology and a 20-year academic career in the Sciences, Pavel is well-placed to identify and understand the technology that underpins R&D Tax Incentive claims across several sectors.

Pavel has also met the requirements for R&D Tax Agent registration and is currently registered with the Australian Government's Tax Practitioners Board.

Global R&D is in regular contact with the regulatory bodies, the Australian Taxation Office and AusIndustry. This enables the business to keep abreast with relevant information relating to the R&D Tax Incentive program, which is shared with our clients.

## Areas of Interest in Taiwan

---

Pharma, Biotech, Medical devices, Drug development, Life Sciences



# Innovative Biotech

## 創新生技

# Audeara Limited



AUDEARA

-  Bill Peng, COO
-  +61 431 897 214
-  [bill.peng@audeara.com](mailto:bill.peng@audeara.com)
-  [audeara.com](http://audeara.com)

## Company Introduction

---

Audeara Limited is a hearing-health technology company delivering personalised audio solutions that improve everyday listening. The Company combines hearing health with consumer audio to create accessible solutions for users seeking enhanced listening without traditional hearing aids. Audeara has expanded globally through partnerships, product development, and technology licensing across

consumer audio and hearing care markets. The Company is advancing Auracast™-enabled accessibility solutions, supporting inclusive audio experiences across public spaces, workplaces, education, and home environments, with applications spanning headphones, earbuds, hearing devices, TV solutions, and broadcast infrastructure.


## Areas of Interest in Taiwan


---


University, Hospital, Retirement Village, Audio Companies






 Thian Chew, Exec Chair and CEO

 +852 5129 8800

 thian.chew@inviongroup.com

 www.inviongroup.com

## Company Introduction

---

Invion (ASX: IVX) is a clinical-stage Australian life sciences company developing its Next-Generation Photodynamic Therapy (NGPDT) for the treatment of a range of cancers. The technology is a precision cancer targeting therapy that is powered by light.

It uses non-toxic photosensitisers activated by a specific wavelength of light to selectively kill cancer cells and promote an anti-cancer immune response.

Highlights of our platform technology for treating cancers include:

- Selectively targets and kills cancer cells by taking advantage of the Warburg effect
- Activation of immune response including when combined with immunotherapies (ICC) increased response rates from 12% to 80%
- Undertaking clinical trials across multiple

cancers and results so far show our treatments to be both safe and demonstrate efficacy signals (awarded Orphan Drug Designation by FDA for anal cancers)


- Industry partners have already recognised the potential of our technology and are providing non-dilutive funding for a number of our programs
- Expanding therapeutic targets to companion animal cancers, where pet pharmaceutical group Protect Animal Health is funding a program
- Theragnostic potential where red light kills cancer cells while violet light causes fluorescence
- Potential for the therapy to be used against infectious diseases (e.g. superbugs) and fungi.


## Areas of Interest in Taiwan

---

- 1) Expand global partnerships and clinical collaborations.
- 2) Raise the profile of the Photosoft technology.
- 3) Leverage government-supported trade mission infrastructure
- 4) Explore clinical trial expansion and regulatory insight.



 Nick Lam, Head, APAC & Patient Outreach

 +61 420 232 174

 [nick.lam@trialscreen.com](mailto:nick.lam@trialscreen.com)

 [trialscreen.org](http://trialscreen.org)

## Company Introduction

---

TrialScreen is a clinical trial search engine that uses AI to make research participation more accessible to patients worldwide. By translating complex registry data from sources like ClinicalTrials.gov, ANZCTR, and ISRCTN into plain-language, patient-friendly formats, TrialScreen removes one of the biggest barriers to clinical trial enrollment: understanding what's available and whether you might be eligible.

The platform powers a suite of products designed to connect patients with research opportunities, including REFER, a pay-per-

lead recruitment tool; TrialFinder, a white-label search engine for sponsors and sites; and ResearchFriends, a patient community built around clinical trial awareness. TrialScreen partners with pharmaceutical sponsors, CROs, patient advocacy groups, and site networks across global markets, with a growing focus on the Asia-Pacific region.

Recognised with the Site Innovation Award at SCOPE Summit 2026 and the Co-Creation & Partnership Award at GPPS25, TrialScreen is reshaping how patients discover and connect with clinical research.

## Areas of Interest in Taiwan

---

Cellular & Regenerative Medicine

Cardiovascular & Metabolic

Thoracic & Respiratory

Multi-Regional Clinical Trials